Special Drug Use Investigation for AMERGE® Tablet (Long-term)

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the long-term safety and efficacy of AMERGE (naratriptan hydrochloride) on Japanese patients with migraine headache in clinical setting

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Naratriptan

Criteria

Inclusion Criteria:

• Must use AMERGE for the first time

Exclusion Criteria:

• Patients with hypersensitivity to naratriptan or any of the components.

• Patients with history, symptoms, or signs of myocardial infarction, ischemic cardiac or angina inversa

• Patients with history of cerebral vascular disturbance or transient ischaemic attack

• Patients with peripheral vascular syndromes

• Patients with uncontrolled hypertension

• Patients with severe renal or hepatic impairment

• Patients using treatment with another 5-HT1 agonist, an ergotamine-containing or ergot-type medication